Myriad Genetics Stock Buy Hold or Sell Recommendation
| MYGN Stock | USD 15.71 0.22 1.42% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Myriad Genetics is 'Cautious Hold'. The recommendation algorithm takes into account all of Myriad Genetics' available fundamental, technical, and predictive indicators you will find on this site.
Check out Myriad Genetics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide. In addition, we conduct extensive research on individual companies such as Myriad and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
Myriad |
Execute Myriad Genetics Buy or Sell Advice
The Myriad recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Myriad Genetics. Macroaxis does not own or have any residual interests in Myriad Genetics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Myriad Genetics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Myriad Genetics Trading Alerts and Improvement Suggestions
| Myriad Genetics generated a negative expected return over the last 90 days | |
| Myriad Genetics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 753.2 M. Net Loss for the year was (263.3 M) with profit before overhead, payroll, taxes, and interest of 476.4 M. | |
| Myriad Genetics currently holds about 205.1 M in cash with (110.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.54. | |
| Myriad Genetics has a poor financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from forbes.com: The Myriad Leader Shifting The Way We Think About Leadership |
Myriad Genetics Returns Distribution Density
The distribution of Myriad Genetics' historical returns is an attempt to chart the uncertainty of Myriad Genetics' future price movements. The chart of the probability distribution of Myriad Genetics daily returns describes the distribution of returns around its average expected value. We use Myriad Genetics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Myriad Genetics returns is essential to provide solid investment advice for Myriad Genetics.
| Mean Return | -0.81 | Value At Risk | -6.12 | Potential Upside | 4.24 | Standard Deviation | 3.45 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Myriad Genetics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Myriad Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Myriad Genetics, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Myriad Genetics back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Dimensional Fund Advisors, Inc. | 2024-09-30 | 2.4 M | Sei Investments Co | 2024-06-30 | 2.4 M | Geode Capital Management, Llc | 2024-09-30 | 2.2 M | Nuveen Asset Management, Llc | 2024-06-30 | 1.4 M | Glenview Capital Management Llc | 2024-09-30 | 1.3 M | D. E. Shaw & Co Lp | 2024-09-30 | 1.2 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.1 M | Point72 Asset Management, L.p. | 2024-09-30 | 1.1 M | Northern Trust Corp | 2024-09-30 | 967.2 K | Blackrock Inc | 2024-06-30 | 15.2 M | Vanguard Group Inc | 2024-09-30 | 10.3 M |
Myriad Genetics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Myriad Genetics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Myriad Genetics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Myriad stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.9 | |
β | Beta against Dow Jones | 0.62 | |
σ | Overall volatility | 3.52 | |
Ir | Information ratio | -0.27 |
Myriad Genetics Volatility Alert
Myriad Genetics exhibits very low volatility with skewness of -1.68 and kurtosis of 9.49. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Myriad Genetics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Myriad Genetics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Myriad Genetics Fundamentals Vs Peers
Comparing Myriad Genetics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Myriad Genetics' direct or indirect competition across all of the common fundamentals between Myriad Genetics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Myriad Genetics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Myriad Genetics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Myriad Genetics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Myriad Genetics to competition |
| Fundamentals | Myriad Genetics | Peer Average |
| Return On Equity | -0.16 | -0.31 |
| Return On Asset | -0.0535 | -0.14 |
| Profit Margin | (0.14) % | (1.27) % |
| Operating Margin | (0.08) % | (5.51) % |
| Current Valuation | 1.45 B | 16.62 B |
| Shares Outstanding | 91.04 M | 571.82 M |
| Shares Owned By Insiders | 2.01 % | 10.09 % |
| Shares Owned By Institutions | 97.99 % | 39.21 % |
| Number Of Shares Shorted | 4.48 M | 4.71 M |
| Price To Earning | 31.95 X | 28.72 X |
| Price To Book | 1.93 X | 9.51 X |
| Price To Sales | 1.71 X | 11.42 X |
| Revenue | 753.2 M | 9.43 B |
| Gross Profit | 476.4 M | 27.38 B |
| EBITDA | (33.9 M) | 3.9 B |
| Net Income | (263.3 M) | 570.98 M |
| Cash And Equivalents | 205.1 M | 2.7 B |
| Cash Per Share | 2.54 X | 5.01 X |
| Total Debt | 363.3 M | 5.32 B |
| Debt To Equity | 0.11 % | 48.70 % |
| Current Ratio | 3.07 X | 2.16 X |
| Book Value Per Share | 8.04 X | 1.93 K |
| Cash Flow From Operations | (110.9 M) | 971.22 M |
| Short Ratio | 7.93 X | 4.00 X |
| Earnings Per Share | (1.28) X | 3.12 X |
| Price To Earnings To Growth | 1.40 X | 4.89 X |
| Target Price | 24.08 | |
| Number Of Employees | 2.7 K | 18.84 K |
| Beta | 1.94 | -0.15 |
| Market Capitalization | 1.41 B | 19.03 B |
| Total Asset | 1.15 B | 29.47 B |
| Retained Earnings | (629.5 M) | 9.33 B |
| Working Capital | 157.7 M | 1.48 B |
Note: Disposition of 2231 shares by Ancona Margaret of Myriad Genetics at 22.72 subject to Rule 16b-3 [view details]
Myriad Genetics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Myriad . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Myriad Genetics Buy or Sell Advice
When is the right time to buy or sell Myriad Genetics? Buying financial instruments such as Myriad Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Myriad Genetics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cash Cows Thematic Idea Now
Cash Cows
Entities with stable and reliable earnings or profits, which allows them to pay consistent dividends to their shareholders. The Cash Cows theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cash Cows Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Myriad Genetics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.28) | Revenue Per Share 9.205 | Quarterly Revenue Growth 0.112 | Return On Assets (0.05) | Return On Equity (0.16) |
The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.